A Phase 3 interventional study of HYCAMTIN, oral capsules and Radiation in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline. Completed at 88 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-20.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 7th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2006, is one of 7 in phase 3, and was the 11th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:
Nuvalent Inc. · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 8
First in 2000; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 472 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 88 across the 47 interventional studies, 1 across the 3 observational. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02817633Tesaro, Inc.A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
Drug: HYCAMTIN, oral capsules · Radiation: Radiation
Whole brain radiation 3 Gy/day for 10 days
Radiation: Radiation
topotecan oral capsules 1.1 mg/m2
Also known as: HYCAMTIN, oral capsules
Whole brain radiation
Overall Survival
Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.
Time frame: From the time of Randomization until the date of death due to any cause (up to 195 weeks)
Six-month Survival
Six-month survival is defined as the percentage of participants alive at 6 months following randomization. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.
Time frame: Month 6
Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic)
The number of participants achieving either a CR or PR, per World Health Organization (WHO) Criteria, in the CNS was assessed. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.
Time frame: From the time of Randomization until the time of CR or PR (up to 75 weeks)
Time to Response (TTR) (CNS-radiologic)
TTR is defined as the time from Randomization until the first documented evidence of CR or PR in the CNS. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.
Time frame: From the time of Randomization until the first documented evidence of CR or PR (up to 75 weeks)
Time to Progression (TTP) (CNS-radiologic)
TTP is defined as the time from Randomization until the first documented sign of disease progression in the CNS. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.
Time frame: From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)
Time to Progression (TTP) (All Sites of Disease-radiologic)
TTP is defined as the time from Randomization until the first documented sign of disease progression in all sites of disease. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.
Time frame: From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)
Number of Participants Who Ranked Each Individual Indicated Neurological Sign and Symptom as None, Mild, Moderate, or Severe at Months 1 and 3
Neurological signs and symptoms data were derived from a participant-reported diary. The participants were asked to assess the following signs and symptoms on a scale of none, mild, moderate, or severe at Months 1 and 3: headache, problems with balance/coordination (PB/C), leg weakness, arm weakness, loss of feeling/numbness (LofF/N), speech difficulty (SD), confusion, loss of memory (LofM), drowsiness, nausea, vomiting, dizziness, visual problems (VP), seizures, leg/ankle swelling (L/AS), heart burn, difficulty sleeping (DS), tiredness, and appetite/weight gain (A/WG).
Time frame: Months 1 and 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Level of Consciousness at Baseline, Month 1, and Month 3
The investigator assessed participants for the neurological sign and symptom of level of consciousness and assigned each participant to one of the following categories: normal; somnolence or sedation not interfering with function (not intefering); somnolence or sedation interfering with function, but not activities of daily living (ADLs) (interfering); obtundation or stupor, difficult to arouse, inteferring with ADLs (obtundation or stupor); coma.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Headache at Baseline, Month 1, and Month 3
The investigator (per Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) assessed participants for headache and assigned each participant to one of the following categories: absent, Grade (G) 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Dizziness/Lightheadedness at Baseline, Month 1, and Month 3
The investigator (per CTCAE, version 3.0) assessed participants for dizziness/lightheadedness and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Vertigo at Baseline, Month 1, and Month 3
The investigator (per CTCAE, version 3.0) assessed participants for vertigo and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Nausea/Vomiting at Baseline, Month 1, and Month 3
The investigator (per CTCAE, version 3.0) assessed participants for nausea/vomiting and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Visual Problem at Baseline, Month 1, and Month 3
The investigator (per CTCAE, version 3.0) assessed participants for visual problem and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Seizure at Baseline, Month 1, and Month 3
The investigator (per CTCAE, version 3.0) assessed participants for seizure and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Other Neurological Symptoms at Baseline, Month 1, and Month 3
The investigator (per CTCAE, version 3.0) assessed participants for other neurological symptoms and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Cranial Nerves II-XII at Baseline, Month 1, and Month 3
The investigator assessed participants' status of cranial nerves II-XII and assigned each participant to one of the following categories: normal; present, not interfering with ADLs; present, interfering with ADLs; life threatening, disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of language (dysphasia or aphasia) and assigned each participant to one of the following categories: absent; awareness of receptive or expressive aphasia, not impairing ability to communicate (not impaired); receptive or expressive dysphasia, impairing ability to communicate (impaired); inability to communicate (unable).
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of strength (right upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Strength (Left Upper Extremity) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of strength (left upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Strength (Right Lower Extremity) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of strength (right lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Strength (Left Lower Extremity) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of strength (left lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Sensation at Baseline, Month 1, and Month 3
The investigator assessed participants' status of sensation and assigned each participant to one of the following categories: normal; loss of deep tendon reflexes or paresthesia, but not interfering with function (not interfering with function); objective sensory loss or paresthesia interfering with function, but not interfering with ADLs (interfering with function); sensory loss or paresthesia interfering with ADLs (intefering with ADLs); permanent sensory loss that interferes with function (permanent sensory loss).
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Ataxia (Right Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of ataxia (right upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Ataxia (Left Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of ataxia (left upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Ataxia (Gait) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of ataxia (gait) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With the Indicated Investigator Assessment of Ataxia (Balance) at Baseline, Month 1, and Month 3
The investigator assessed participants' status of ataxia (balance) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
Time frame: Baseline, Month 1, and Month 3
Number of Participants With Any Adverse Event (AE; Both Serious and Non-serious) or Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect. For a list of all SAEs and AEs, see the SAE/AE module of this results summary.
Time frame: From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)
Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Chemistry Parameters With Respect to the Normal Range
The worst-case change from Baseline in chemistry parameters was measured as decrease to low (DTL), change to normal or no change (CTN/NC), or increase to high (ITH). The worst-case change value could have been measured at any point during the on-therapy period. Participants are counted twice if the participant "Decreased to Low" and "Increased to High" during the on-therapy period.
Time frame: From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)
Lesion Assessment and Measurement
Lesions were assessed per WHO criteria. For lesion assessment data, see the outcome measure entitled "Number of participants with a complete response (CR) or a partial response (PR) (central nervous system \[CNS\]-radiologic)."
Time frame: From the time of Randomization until the time of CR or PR (up to 75 weeks)
Brain Symptoms
Brain symptoms were assessed as the number of participants with neurological signs and symptoms. For brain symptom data, see the outcome measures entitled "Number of participants with the indicated investigator assessment for the neurological sign and symptom of X at Baseline, Month 1, and Month 3."
Time frame: Baseline, Month 1, and Month 3
Number of Participants Who Died or Progressed
Disease-related events were measured as the number of participants who died or progressed. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. Data were analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before an event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.
Time frame: From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)
| Milestone | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Started | 236 | 236 |
| Ongoing | 4 | 2 |
| Completed | 206 | 204 |
| Not completed | 30 | 32 |
| Withdrew: Lost to follow-up | 7 | 6 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Withdrawal by subject | 12 | 15 |
| Withdrew: Investigator decision | 4 | 6 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Ongoing | 4 | 2 |
Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.
| months | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Overall Survival | 4.0 (3.4 to 4.8) | 3.6 (3.0 to 4.0) |
Six-month survival is defined as the percentage of participants alive at 6 months following randomization. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.
| percentage of participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Six-month Survival | 36 | 28 |
The number of participants achieving either a CR or PR, per World Health Organization (WHO) Criteria, in the CNS was assessed. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Complete response | 23 | 11 |
| Partial response | 63 | 61 |
TTR is defined as the time from Randomization until the first documented evidence of CR or PR in the CNS. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.
| weeks | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Time to Response (TTR) (CNS-radiologic) | 8.0 (7.7 to 8.1) | 8.1 (6.0 to 8.1) |
TTP is defined as the time from Randomization until the first documented sign of disease progression in the CNS. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.
| weeks | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Time to Progression (TTP) (CNS-radiologic) | 9.7 (8.1 to 13.9) | 9.7 (8.3 to 10.9) |
TTP is defined as the time from Randomization until the first documented sign of disease progression in all sites of disease. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.
| weeks | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Time to Progression (TTP) (All Sites of Disease-radiologic) | 8.0 (6.7 to 8.7) | 7.7 (6.1 to 8.1) |
Neurological signs and symptoms data were derived from a participant-reported diary. The participants were asked to assess the following signs and symptoms on a scale of none, mild, moderate, or severe at Months 1 and 3: headache, problems with balance/coordination (PB/C), leg weakness, arm weakness, loss of feeling/numbness (LofF/N), speech difficulty (SD), confusion, loss of memory (LofM), drowsiness, nausea, vomiting, dizziness, visual problems (VP), seizures, leg/ankle swelling (L/AS), heart burn, difficulty sleeping (DS), tiredness, and appetite/weight gain (A/WG).
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Headache, Month 1, none, n=179, 189 | 93 | 106 |
| Headache, Month 1, mild, n=179, 189 | 71 | 68 |
| Headache, Month 1, moderate, 179, 189 | 11 | 13 |
| Headache, Month 1, severe, 179, 189 | 4 | 2 |
| Headache, Month 3, none, n=109, 111 | 69 | 53 |
| Headache, Month 3, mild, n=109, 111 | 33 | 41 |
| Headache, Month 3, moderate, n=109, 111 | 5 | 14 |
| Headache, Month 3, severe, n=109, 111 | 2 | 3 |
| PB/C, Month 1, none, n=179, 188 | 84 | 79 |
| PB/C, Month 1, mild, n=179, 188 | 66 | 71 |
| PB/C, Month 1, moderate, n=179, 188 | 22 | 30 |
| PB/C, Month 1, severe, n=179, 188 | 7 | 8 |
| PB/C, Month 3, none, n=109, 111 | 69 | 46 |
| PB/C, Month 3, mild, n=109, 111 | 28 | 36 |
| PB/C, Month 3, moderate, n=109, 111 | 10 | 18 |
| PB/C, Month 3, severe, n=109, 111 | 2 | 11 |
| Leg weakness, Month 1, none, n=179, 188 | 47 | 59 |
| Leg weakness, Month 1, mild, n=179, 188 | 73 | 72 |
| Leg weakness, Month 1, moderate, n=179, 188 | 41 | 41 |
| Leg weakness, Month 1, severe, n=179, 188 | 18 | 16 |
| Leg weakness, Month 3, none, n=109, 111 | 28 | 34 |
| Leg weakness, Month 3, mild, n=109, 111 | 51 | 37 |
| Leg weakness, Month 3, moderate, n=109, 111 | 20 | 19 |
| Leg weakness, Month 3, severe, n=109, 111 | 10 | 21 |
| Arm weakness, Month 1, none, n=179, 188 | 96 | 97 |
| Arm weakness, Month 1, mild, n=179, 188 | 55 | 60 |
| Arm weakness, Month 1, moderate, n=179, 188 | 23 | 18 |
| Arm weakness, Month 1, severe, n=179, 188 | 5 | 13 |
| Arm weakness, Month 3, none, n=109, 111 | 60 | 53 |
| Arm weakness, Month 3, mild, n=109, 111 | 39 | 34 |
| Arm weakness, Month 3, molderate, n=109, 111 | 8 | 16 |
| Arm weakness, Month 3, severe, n=109, 111 | 2 | 8 |
| LofF/N, Month 1, none, n=179, 188 | 101 | 11 |
| LofF/N, Month 1, mild, n=179, 188 | 53 | 43 |
| LofF/N, Month 1, moderate, n=179, 188 | 17 | 25 |
| LofF/N, Month 1, severe, n=179, 188 | 8 | 9 |
| LofF/N, Month 3, none, n=109, 111 | 73 | 66 |
| LofF/N, Month 3, mild, n=109, 111 | 28 | 27 |
| LofF/N, Month 3, moderate, n=109, 111 | 3 | 11 |
| LofF/N, Month 3, severe, n=109, 111 | 5 | 7 |
| SD, Month 1, none, n=179, 188 | 151 | 137 |
| SD, Month 1, mild, n=179, 188 | 16 | 40 |
| SD, Month 1, moderate, n=179, 188 | 9 | 9 |
| SD, Month 1, severe, n=179, 188 | 3 | 2 |
| SD, Month 3, none, n=109, 110 | 94 | 78 |
| SD, Month 3, mild, n=109, 110 | 11 | 22 |
| SD, Month 3, moderate, n=109, 110 | 2 | 8 |
| SD, Month 3, severe, n=109, 110 | 2 | 2 |
| Confusion, Month 1, none, n=179, 188 | 150 | 148 |
| Confusion, Month 1, mild, n=179, 188 | 20 | 32 |
| Confusion, Month 1, moderate, n=179, 188 | 6 | 7 |
| Confusion, Month 1, severe, n=179, 188 | 3 | 1 |
| Confusion, Month 3, none, n=109, 110 | 99 | 71 |
| Confusion, Month 3, mild, n=109, 110 | 7 | 29 |
| Confusion, Month 3, moderate, n=109, 110 | 2 | 9 |
| Confusion, Month 3, severe, n=109, 110 | 1 | 1 |
| LofM, Month 1, none, n=179, 188 | 149 | 141 |
| LofM, Month 1, mild, n=179, 188 | 20 | 41 |
| LofM, Month 1, moderate, n=179, 188 | 8 | 5 |
| LofM, Month 1, severe, n=179, 188 | 2 | 1 |
| LofM, Month 3, none, n=109, 110 | 93 | 78 |
| LofM, Month 3, mild, n=109, 110 | 14 | 25 |
| LofM, Month 3, moderate, n=109, 110 | 1 | 6 |
| LofM, Month 3, severe, n=109, 110 | 1 | 1 |
| Drowsiness, Month 1, none, n=179, 188 | 90 | 96 |
| Drowsiness, Month 1, mild, n=179, 188 | 55 | 59 |
| Drowsiness, Month 1, moderate, n=179, 188 | 25 | 26 |
| Drowsiness, Month 1, severe, n=179, 188 | 9 | 7 |
| Drowsiness, Month 3, none, n=109, 111 | 50 | 44 |
| Drowsiness, Month 3, mild, n=109, 111 | 42 | 40 |
| Drowsiness, Month 3, moderate, n=109, 111 | 15 | 15 |
| Drowsiness, Month 3, severe, n=109, 111 | 2 | 12 |
| Nausea, Month 1, none, n=179, 188 | 125 | 142 |
| Nausea, Month 1, mild, n=179, 188 | 38 | 36 |
| Nausea, Month 1, moderate, n=179, 188 | 12 | 10 |
| Nausea, Month 1, severe, n=179, 188 | 4 | 0 |
| Nausea, Month 3, none, n=109, 111 | 70 | 73 |
| Nausea, Month 3, mild, n=109, 111 | 31 | 29 |
| Nausea, Month 3, moderate, n=109, 111 | 7 | 6 |
| Nausea, Month 3, severe, n=109, 111 | 1 | 3 |
| Vomiting, Month 1, none, n=179, 188 | 153 | 164 |
| Vomiting, Month 1, mild, n=179, 188 | 20 | 19 |
| Vomiting, Month 1, moderate, n=179, 188 | 4 | 4 |
| Vomiting, Month 1, severe, n=179, 188 | 2 | 1 |
| Vomiting, Month 3, none, n=109, 111 | 89 | 91 |
| Vomiting, Month 3, mild, n=109, 111 | 15 | 15 |
| Vomiting, Month 3, moderate, n=109, 111 | 4 | 3 |
| Vomiting, Month 3, severe=109, 111 | 1 | 2 |
| Dizziness, Month 1, none, n=179, 188 | 96 | 94 |
| Dizziness, Month 1, mild, n=179, 188 | 58 | 70 |
| Dizziness, Month 1, moderate, n=179, 188 | 22 | 21 |
| Dizziness, Month 1, severe, n=179, 188 | 3 | 3 |
| Dizziness, Month 3, none, n=109, 111 | 64 | 54 |
| Dizziness, Month 3, mild, n=109, 111 | 35 | 36 |
| Dizziness, Month 3, moderate, n=109, 111 | 7 | 14 |
| Dizziness, Month 3, severe, n=109, 111 | 3 | 7 |
| VP, Month 1, none, n=179, 188 | 103 | 117 |
| VP, Month 1, mild, n=179, 188 | 54 | 53 |
| VP, Month 1, moderate, n=179, 188 | 17 | 16 |
| VP, Month 1, severe, n=179, 188 | 5 | 2 |
| VP, Month 3, none, n=109, 111 | 72 | 69 |
| VP, Month 3, mild, n=109, 111 | 29 | 28 |
| VP, Month 3, moderate, n=109, 111 | 7 | 10 |
| VP, Month 3, severe, n=109, 111 | 1 | 4 |
| Seizures, Month 1, none, n=179, 188 | 173 | 179 |
| Seizures, Month 1, mild, n=179, 188 | 5 | 7 |
| Seizures, Month 1, moderate, n=179, 188 | 1 | 2 |
| Seizures, Month 1, severe, n=179, 188 | 0 | 0 |
| Seizures, Month 3, none, n=109, 110 | 108 | 102 |
| Seizures, Month 3, mild, n=109, 110 | 0 | 4 |
| Seizures, Month 3, moderate, n=109, 110 | 1 | 3 |
| Seizures, Month 3, severe, n=109, 110 | 0 | 1 |
| L/AS, Month 1, none, n=179, 188 | 141 | 138 |
| L/AS, Month 1, mild, n=179, 188 | 21 | 29 |
| L/AS, Month 1, moderate, n=179, 188 | 12 | 15 |
| L/AS, Month 1, severe, n=179, 188 | 5 | 6 |
| L/AS, Month 3, none, n=109, 111 | 86 | 85 |
| L/AS, Month 3, mild, n=109, 111 | 19 | 19 |
| L/AS, Month 3, moderate, n=109, 111 | 3 | 6 |
| L/AS, Month 3, severe, n=109, 111 | 1 | 1 |
| Heartburn, Month 1, none, n=179, 188 | 142 | 151 |
| Heartburn, Month 1, mild, n=179, 188 | 26 | 27 |
| Heartburn, Month 1, moderate, n=179, 188 | 9 | 9 |
| Heartburn, Month 1, severe, n=179, 188 | 2 | 1 |
| Heartburn, Month 3, none, n=109, 111 | 87 | 86 |
| Heartburn, Month 3, mild, n=109, 111 | 16 | 18 |
| Heartburn, Month 3, moderate, n=109, 111 | 4 | 6 |
| Heartburn, Month 3, severe, n=109, 111 | 2 | 1 |
| DS, Month 1, none, n=179, 188 | 112 | 109 |
| DS, Month 1, mild, n=179, 188 | 41 | 48 |
| DS, Month 1, moderate, n=179, 188 | 15 | 24 |
| DS, Month 1, severe, n=179, 188 | 11 | 7 |
| DS, Month 3, none, n=109, 110 | 78 | 71 |
| DS, Month 3, mild, n=109, 110 | 20 | 23 |
| DS, Month 3, moderate, n=109, 110 | 8 | 12 |
| DS, Month 3, severe, n=109, 110 | 3 | 4 |
| Tiredness, Month 1, none, n=179, 188 | 42 | 42 |
| Tiredness, Month 1, mild, n=179, 188 | 75 | 85 |
| Tiredness, Month 1, moderate, n=179, 188 | 46 | 44 |
| Tiredness, Month 1, severe, n=179, 188 | 16 | 17 |
| Tiredness, Month 3, none, n=109, 111 | 28 | 21 |
| Tiredness, Month 3, mild, n=109, 111 | 52 | 42 |
| Tiredness, Month 3, moderate, n=109, 111 | 19 | 32 |
| Tiredness, Month 3, severe, n=109, 111 | 10 | 16 |
| A/WG, Month 1, none, n=179, 188 | 107 | 113 |
| A/WG, Month 1, mild, n=179, 188 | 42 | 41 |
| A/WG, Month 1, moderate, n=179, 188 | 19 | 29 |
| A/WG, Month 1, severe, n=179, 188 | 11 | 5 |
| A/WG, Month 3, none, n=108, 111 | 71 | 73 |
| A/WG, Month 3, mild, n=108, 111 | 27 | 23 |
| A/WG, Month 3, moderate, n=108, 111 | 4 | 11 |
| A/WG, Month 3, severe, n=108, 111 | 6 | 4 |
The investigator assessed participants for the neurological sign and symptom of level of consciousness and assigned each participant to one of the following categories: normal; somnolence or sedation not interfering with function (not intefering); somnolence or sedation interfering with function, but not activities of daily living (ADLs) (interfering); obtundation or stupor, difficult to arouse, inteferring with ADLs (obtundation or stupor); coma.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 228 | 219 | 216 |
| Month 1, normal, n=178, 180 | 171 | 169 |
| Month 3, normal, n=109, 107 | 102 | 92 |
| Baseline, not interfering, n=230, 228 | 7 | 9 |
| Month 1, not interfering, n=178, 180 | 5 | 7 |
| Month 3, not interfering, n=109, 107 | 3 | 8 |
| Baseline, interfering, n=230, 228 | 3 | 3 |
| Month 1, interfering, n=178, 180 | 0 | 4 |
| Month 3, interfering, n=109, 107 | 3 | 5 |
| Baseline, obtundation and stupor, n=230, 228 | 1 | 0 |
| Month 1, obtundation and stupor, n=178, 180 | 2 | 0 |
| Month 3, obtundation and stupor, n=109, 107 | 1 | 2 |
The investigator (per Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) assessed participants for headache and assigned each participant to one of the following categories: absent, Grade (G) 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=230, 228 | 141 | 146 |
| Month 1, absent, n=178, 180 | 126 | 127 |
| Month 3, absent, n=109, 107 | 85 | 74 |
| Baseline, Grade 1, n=230, 228 | 62 | 55 |
| Month 1, Grade 1, n=178, 180 | 43 | 38 |
| Month 3, Grade 1, n=109, 107 | 17 | 23 |
| Baseline, Grade 2, n=230, 228 | 25 | 23 |
| Month 1, Grade 2, n=178, 180 | 9 | 14 |
| Month 3, Grade 2, n=109, 107 | 7 | 10 |
| Baseline, Grade 3, n=230, 228 | 2 | 4 |
| Month 1, Grade 3, n=178, 180 | 0 | 1 |
The investigator (per CTCAE, version 3.0) assessed participants for dizziness/lightheadedness and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=230, 228 | 160 | 151 |
| Month 1, absent, n=178, 180 | 124 | 128 |
| Month 3, absent, n=109, 107 | 76 | 76 |
| Baseline, Grade 1, n=230, 228 | 45 | 47 |
| Month 1, Grade 1, n=178, 180 | 44 | 36 |
| Month 3, Grade 1, n=109, 107 | 21 | 20 |
| Baseline, Grade 2, n=230, 228 | 21 | 26 |
| Month 1, Grade 2, n=178, 180 | 7 | 14 |
| Month 3, Grade 2, n=109, 107 | 9 | 9 |
| Baseline, Grade 3, n=230, 228 | 4 | 4 |
| Month 1, Grade 3, n=178, 180 | 3 | 2 |
| Month 3, Grade 3, n=109, 107 | 3 | 2 |
The investigator (per CTCAE, version 3.0) assessed participants for vertigo and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=230, 228 | 180 | 173 |
| Month 1, absent, n=178, 180 | 148 | 150 |
| Month 3, absent, n=109, 107 | 90 | 86 |
| Baseline, Grade 1, n=230, 228 | 26 | 30 |
| Month 1, Grade 1, n=178, 180 | 19 | 19 |
| Month 3, Grade 1, n=109, 107 | 14 | 13 |
| Baseline, Grade 2, n=230, 228 | 19 | 22 |
| Month 1, Grade 2, n=178, 180 | 7 | 9 |
| Month 3, Grade 2, n=109, 107 | 4 | 6 |
| Baseline, Grade 3, n=230, 228 | 5 | 3 |
| Month 1, Grade 3, n=178, 180 | 3 | 2 |
| Month 3, Grade 3, n=109, 107 | 1 | 2 |
| Month 1, Grade 4, n=178, 180 | 1 | 0 |
The investigator (per CTCAE, version 3.0) assessed participants for nausea/vomiting and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=230, 228 | 203 | 192 |
| Month 1, absent, n=178, 180 | 151 | 162 |
| Month 3, absent, n=109, 107 | 88 | 93 |
| Baseline, Grade 1, n=230, 228 | 19 | 22 |
| Month 1, Grade 1, n=178, 180 | 20 | 15 |
| Month 3, Grade 1, n=109, 107 | 14 | 11 |
| Baseline, Grade 2, n=230, 228 | 7 | 10 |
| Month 1, Grade 2, n=178, 180 | 6 | 3 |
| Month 3, Grade 2, n=109, 107 | 6 | 3 |
| Baseline, Grade 3, n=230, 228 | 1 | 4 |
| Month 1, Grade 3, n=178, 180 | 1 | 0 |
| Month 3, Grade 5, n=109, 107 | 1 | 0 |
The investigator (per CTCAE, version 3.0) assessed participants for visual problem and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=230, 228 | 181 | 189 |
| Month 1, absent, n=178, 180 | 148 | 154 |
| Month 3, absent, n=109, 107 | 93 | 93 |
| Baseline, Grade 1, n=230, 228 | 22 | 25 |
| Month 1, Grade 1, n=178, 180 | 16 | 19 |
| Month 3, Grade 1, n=109, 107 | 12 | 10 |
| Baseline, Grade 2, n=230, 228 | 20 | 13 |
| Month 1, Grade 2, n=178, 180 | 11 | 6 |
| Month 3, Grade 2, n=109, 107 | 4 | 3 |
| Baseline, Grade 3, n=230, 228 | 5 | 1 |
| Month 1, Grade 3, n=178, 180 | 2 | 1 |
| Month 3, Grade 3, n=109, 107 | 0 | 1 |
| Baseline, Grade 4, n=230, 228 | 2 | 0 |
| Month 1, Grade 4, n=178, 180 | 1 | 0 |
The investigator (per CTCAE, version 3.0) assessed participants for seizure and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=230, 228 | 218 | 216 |
| Month 1, absent, n=178, 180 | 175 | 178 |
| Month 3, absent, n=109, 107 | 109 | 101 |
| Baseline, Grade 1, n=230, 228 | 4 | 6 |
| Month 1, Grade 1, n=178, 180 | 2 | 1 |
| Month 3, Grade 1, n=109, 107 | 0 | 4 |
| Baseline, Grade 2, n=230, 228 | 6 | 6 |
| Month 1, Grade 2, n=178, 180 | 1 | 1 |
| Month 3, Grade 2, n=109, 107 | 0 | 2 |
| Baseline, Grade 3, n=230, 228 | 1 | 0 |
| Baseline, Grade 4, n=230, 228 | 1 | 0 |
The investigator (per CTCAE, version 3.0) assessed participants for other neurological symptoms and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=229, 228 | 219 | 214 |
| Month 1, absent, n=177, 180 | 165 | 171 |
| Month 3, absent, n=109, 107 | 99 | 101 |
| Baseline, Grade 1, n=229, 228 | 2 | 5 |
| Month 1, Grade 1, n=177, 180 | 2 | 6 |
| Month 3, Grade 1, n=109, 107 | 6 | 5 |
| Baseline, Grade 2, n=229, 228 | 7 | 8 |
| Month 1, Grade 2, n=177, 180 | 8 | 1 |
| Month 3, Grade 2, n=109, 107 | 3 | 1 |
| Baseline, Grade 3, n=229, 228 | 1 | 1 |
| Month 1, Grade 3, n=177, 180 | 2 | 1 |
| Month 1, Grade 4, n=177, 180 | 0 | 1 |
| Month 3, Grade 5, n=109, 107 | 1 | 0 |
The investigator assessed participants' status of cranial nerves II-XII and assigned each participant to one of the following categories: normal; present, not interfering with ADLs; present, interfering with ADLs; life threatening, disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=229, 225 | 218 | 211 |
| Month 1, normal, n=177, 179 | 172 | 169 |
| Month 3, normal, n=109, 107 | 106 | 102 |
| Baseline, present, not interfering, n=229, 225 | 11 | 10 |
| Month 1, present, not interfering, n=177, 179 | 4 | 6 |
| Month 3, present, not interfering, n=109, 107 | 3 | 2 |
| Baseline, present, interfering, n=229, 225 | 0 | 4 |
| Month 1, present, interfering, n=177, 179 | 1 | 4 |
| Month 3, present, interfering, n=109, 107 | 0 | 3 |
The investigator assessed participants' status of language (dysphasia or aphasia) and assigned each participant to one of the following categories: absent; awareness of receptive or expressive aphasia, not impairing ability to communicate (not impaired); receptive or expressive dysphasia, impairing ability to communicate (impaired); inability to communicate (unable).
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, absent, n=230, 228 | 211 | 215 |
| Month 1, absent, n=178, 180 | 169 | 173 |
| Month 3, absent, n=109, 107 | 105 | 98 |
| Baseline, not impaired, n=230, 228 | 15 | 10 |
| Month 1, not impaired, n=178, 180 | 6 | 5 |
| Month 3, not impaired, n=109, 107 | 3 | 7 |
| Baseline, impaired, n=230, 228 | 3 | 3 |
| Month 1, impaired, n=178, 180 | 3 | 2 |
| Month 3, impaired, n=109, 107 | 1 | 0 |
| Baseline, unable, n=230, 228 | 1 | 0 |
| Month 3, unable, n=109, 107 | 0 | 2 |
The investigator assessed participants' status of strength (right upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 228 | 203 | 195 |
| Month 1, normal, n=178, 179 | 153 | 159 |
| Month 3, normal, n=109, 107 | 93 | 89 |
| Baseline, Grade 1, n=230, 228 | 15 | 16 |
| Month 1, Grade 1, n=178, 179 | 13 | 12 |
| Month 3, Grade 1, n=109, 107 | 10 | 10 |
| Baseline, Grade 2, n=230, 228 | 6 | 12 |
| Month 1, Grade 2, n=178, 179 | 6 | 5 |
| Month 3, Grade 2, n=109, 107 | 4 | 5 |
| Baseline, Grade 3, n=230, 228 | 5 | 5 |
| Month 1, Grade 3, n=178, 179 | 4 | 2 |
| Month 3, Grade 3, n=109, 107 | 2 | 3 |
| Baseline, Grade 4, n=230, 228 | 1 | 0 |
| Month 1, Grade 4, n=178, 179 | 2 | 1 |
The investigator assessed participants' status of strength (left upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 228 | 197 | 202 |
| Month 1, normal, n=178, 179 | 149 | 157 |
| Month 3, normal, n=109, 107 | 90 | 86 |
| Baseline, Grade 1, n=230, 228 | 16 | 13 |
| Month 1, Grade 1, n=178, 179 | 16 | 13 |
| Month 3, Grade 1, n=109, 107 | 10 | 11 |
| Baseline, Grade 2, n=230, 228 | 11 | 8 |
| Month 1, Grade 2, n=178, 179 | 8 | 5 |
| Month 3, Grade 2, n=109, 107 | 6 | 5 |
| Baseline, Grade 3, n=230, 228 | 6 | 4 |
| Month 1, Grade 3, n=178, 179 | 3 | 2 |
| Month 3, Grade 3, n=109, 107 | 3 | 4 |
| Baseline, Grade 4, n=230, 228 | 0 | 1 |
| Month 1, Grade 4, n=178, 179 | 2 | 2 |
| Month 3, Grade 4, n=109, 107 | 0 | 1 |
The investigator assessed participants' status of strength (right lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 228 | 196 | 189 |
| Month 1, normal, n=178, 180 | 137 | 145 |
| Month 3, normal, n=109, 107 | 81 | 80 |
| Baseline, Grade 1, n=230, 228 | 20 | 19 |
| Month 1, Grade 1, n=178, 180 | 17 | 15 |
| Month 3, Grade 1, n=109, 107 | 12 | 11 |
| Baseline, Grade 2, n=230, 228 | 9 | 16 |
| Month 1, Grade 2, n=178, 180 | 11 | 19 |
| Month 3, Grade 2, n=109, 107 | 11 | 11 |
| Baseline, Grade 3, n=230, 228 | 3 | 4 |
| Month 1, Grade 3, n=178, 180 | 9 | 0 |
| Month 3, Grade 3, n=109, 107 | 4 | 3 |
| Baseline, Grade 4, n=230, 228 | 2 | 0 |
| Month 1, Grade 4, n=178, 180 | 4 | 1 |
| Month 3, Grade 4, n=109, 107 | 1 | 2 |
The investigator assessed participants' status of strength (left lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 228 | 182 | 190 |
| Month 1, normal, n=178, 179 | 128 | 143 |
| Month 3, normal, n=109, 107 | 76 | 73 |
| Baseline, Grade 1, n=230, 228 | 28 | 18 |
| Month 1, Grade 1, n=178, 179 | 26 | 13 |
| Month 3, Grade 1, n=109, 107 | 11 | 11 |
| Baseline, Grade 2, n=230, 228 | 15 | 15 |
| Month 1, Grade 2, n=178, 179 | 11 | 17 |
| Month 3, Grade 2, n=109, 107 | 14 | 14 |
| Baseline, Grade 3, n=230, 228 | 4 | 3 |
| Month 1, Grade 3, n=178, 179 | 10 | 4 |
| Month 3, Grade 3, n=109, 107 | 6 | 5 |
| Baseline, Grade 4, n=230, 228 | 1 | 2 |
| Month 1, Grade 4, n=178, 179 | 3 | 2 |
| Month 3, Grade 4, n=109, 107 | 2 | 4 |
The investigator assessed participants' status of sensation and assigned each participant to one of the following categories: normal; loss of deep tendon reflexes or paresthesia, but not interfering with function (not interfering with function); objective sensory loss or paresthesia interfering with function, but not interfering with ADLs (interfering with function); sensory loss or paresthesia interfering with ADLs (intefering with ADLs); permanent sensory loss that interferes with function (permanent sensory loss).
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline (BL), normal, n=230, 228 | 197 | 192 |
| Month (M) 1, normal, n=178, 180 | 144 | 159 |
| Month 3, normal, n=109, 107 | 100 | 94 |
| BL, not interfering with function, n=230, 228 | 26 | 26 |
| M 1, not interfering with function, n=178, 180 | 22 | 15 |
| M 3, not interfering with function, n=109, 107 | 5 | 9 |
| BL, interfering with function, n=230, 228 | 3 | 6 |
| M 1, interfering with function, n=178, 180 | 7 | 4 |
| M 3, interfering with function, n=109, 107 | 2 | 2 |
| Baseline, interfering with ADLs, n=230, 228 | 4 | 3 |
| Month 1, interfering with ADLs, n=178, 180 | 5 | 2 |
| Month 3, interfering with ADLs, n=109, 107 | 2 | 2 |
| Baseline, permanent sensory loss, n=230, 228 | 0 | 1 |
The investigator assessed participants' status of ataxia (right upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=229, 228 | 206 | 198 |
| Month 1, normal, 178, 179 | 166 | 166 |
| Month 3, normal, n=109, 107 | 103 | 95 |
| Baseline, Grade 1, n=229, 228 | 13 | 17 |
| Month 1, Grade 1, 178, 179 | 7 | 6 |
| Month 3, Grade 1, n=109, 107 | 6 | 5 |
| Baseline, Grade 2, n=229, 228 | 5 | 12 |
| Month 1, Grade 2, 178, 179 | 3 | 6 |
| Month 3, Grade 2, n=109, 107 | 0 | 5 |
| Baseline, Grade 3, n=229, 228 | 3 | 1 |
| Month 3, Grade 3, n=109, 107 | 0 | 1 |
| Baseline, Grade 4, n=229, 228 | 2 | 0 |
| Month 1, Grade 4, 178, 179 | 2 | 1 |
| Month 3, Grade 4, n=109, 107 | 0 | 1 |
The investigator assessed participants' status of ataxia (left upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 227 | 199 | 201 |
| Month 1, normal, n=178, 178 | 156 | 162 |
| Month 3, normal, n=109, 107 | 97 | 94 |
| Baseline, Grade 1, n=230, 227 | 15 | 13 |
| Month 1, Grade 1, n=178, 178 | 14 | 9 |
| Month 3, Grade 1, n=109, 107 | 10 | 6 |
| Baseline, Grade 2, n=230, 227 | 8 | 7 |
| Month 1, Grade 2, n=178, 178 | 6 | 3 |
| Month 3, Grade 2, n=109, 107 | 2 | 3 |
| Baseline, Grade 3, n=230, 227 | 8 | 4 |
| Month 1, Grade 3, n=178, 178 | 0 | 3 |
| Month 3, Grade 3, n=109, 107 | 0 | 1 |
| Baseline, Grade 4, n=230, 227 | 0 | 2 |
| Month 1, Grade 4, n=178, 178 | 2 | 1 |
| Month 3, Grade 4, n=109, 107 | 0 | 3 |
The investigator assessed participants' status of ataxia (gait) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 227 | 172 | 178 |
| Month 1, normal, n=178, 179 | 138 | 147 |
| Month 3, normal, n=108, 107 | 85 | 76 |
| Baseline, Grade 1, n=230, 227 | 13 | 22 |
| Month 1, Grade 1, n=178, 179 | 16 | 13 |
| Month 3, Grade 1, n=108, 107 | 9 | 10 |
| Baseline, Grade 2, n=230, 227 | 37 | 20 |
| Month 1, Grade 2, n=178, 179 | 14 | 14 |
| Month 3, Grade 2, n=108, 107 | 9 | 12 |
| Baseline, Grade 3, n=230, 227 | 6 | 6 |
| Month 1, Grade 3, n=178, 179 | 7 | 3 |
| Month 3, Grade 3, n=108, 107 | 4 | 5 |
| Baseline, Grade 4, n=230, 227 | 2 | 1 |
| Month 1, Grade 4, n=178, 179 | 3 | 2 |
| Month 3, Grade 4, n=108, 107 | 1 | 4 |
The investigator assessed participants' status of ataxia (balance) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Baseline, normal, n=230, 228 | 153 | 152 |
| Month 1, normal, n=178, 178 | 131 | 128 |
| Month 3, normal, n=108, 107 | 78 | 75 |
| Baseline, Grade 1, n=230, 228 | 37 | 44 |
| Month 1, Grade 1, n=178, 178 | 23 | 28 |
| Month 3, Grade 1, n=108, 107 | 17 | 13 |
| Baseline, Grade 2, n=230, 228 | 27 | 23 |
| Month 1, Grade 2, n=178, 178 | 13 | 16 |
| Month 3, Grade 2, n=108, 107 | 8 | 9 |
| Baseline, Grade 3, n=230, 228 | 10 | 7 |
| Month 1, Grade 3, n=178, 178 | 8 | 5 |
| Month 3, Grade 3, n=108, 107 | 4 | 5 |
| Baseline, Grade 4, n=230, 228 | 3 | 2 |
| Month 1, Grade 4, n=178, 178 | 3 | 1 |
| Month 3, Grade 4, n=108, 107 | 1 | 5 |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect. For a list of all SAEs and AEs, see the SAE/AE module of this results summary.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| AE | 204 | 148 |
| SAE | 96 | 43 |
The worst-case change from Baseline in chemistry parameters was measured as decrease to low (DTL), change to normal or no change (CTN/NC), or increase to high (ITH). The worst-case change value could have been measured at any point during the on-therapy period. Participants are counted twice if the participant "Decreased to Low" and "Increased to High" during the on-therapy period.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Chloride, DTL, n=169, 171 | 32 | 21 |
| Chloride, CTN/NC, n=169, 171 | 116 | 144 |
| Chloride, ITH, n=169, 171 | 22 | 6 |
| Creatinine clearance, DTL, n=159, 145 | 26 | 9 |
| Creatinine clearance, CTN/NC, n=159, 145 | 121 | 134 |
| Creatinine clearance, ITH, n=159, 145 | 15 | 2 |
| Lactate dehydrogenase, DTL, n=169, 168 | 8 | 1 |
| Lactate dehydrogenase, CTN/NC, n=169, 168 | 117 | 127 |
| Lactate dehydrogenase, ITH, n=169, 168 | 47 | 40 |
| Total protein, DTL, n=171, 175 | 48 | 36 |
| Total protein, CTN/NC, n=171, 175 | 119 | 137 |
| Total protein, ITH, n=171, 175 | 4 | 2 |
| Urea/blood urea nitrogen, DTL, n=178, 179 | 7 | 4 |
| Urea/blood urea nitrogen, CTN/NC, n=178, 179 | 139 | 152 |
| Urea/blood urea nitrogen, ITH, n=178, 179 | 33 | 24 |
| Uric acid, DTL, n=159, 152 | 21 | 12 |
| Uric acid, CTN/NC, n=159, 152 | 125 | 134 |
| Uric acid, ITH, n=159, 152 | 13 | 6 |
| Basophils, DTL, n=215, 211 | 7 | 1 |
| Basophils, CTN/NC, n=215, 211 | 186 | 200 |
| Basophils, ITH, n=215, 211 | 25 | 10 |
| Eosinophils, DTL, n=214, 211 | 28 | 12 |
| Eosinophils, CTN/NC, n=214, 211 | 182 | 191 |
| Eosinophils, ITH, n=214, 211 | 4 | 8 |
| Hematocrit, DTL, n=215, 212 | 98 | 38 |
| Hematocrit, CTN/NC, n=215, 212 | 117 | 169 |
| Hematocrit, ITH, n=215, 212 | 1 | 6 |
| Monocytes, DTL, n=216, 212 | 84 | 17 |
| Monocytes, CTN/NC, n=216, 212 | 119 | 161 |
| Monocytes, ITH, n=216, 212 | 54 | 37 |
| Red Blood Cell Count, DTL, n=216, 212 | 103 | 38 |
| Red Blood Cell Count, CTN/NC, n=216, 212 | 113 | 171 |
| Red Blood Cell Count, ITH, n=216, 212 | 0 | 4 |
Lesions were assessed per WHO criteria. For lesion assessment data, see the outcome measure entitled "Number of participants with a complete response (CR) or a partial response (PR) (central nervous system \[CNS\]-radiologic)."
No measurements were reported for this outcome.
Brain symptoms were assessed as the number of participants with neurological signs and symptoms. For brain symptom data, see the outcome measures entitled "Number of participants with the indicated investigator assessment for the neurological sign and symptom of X at Baseline, Month 1, and Month 3."
No measurements were reported for this outcome.
Disease-related events were measured as the number of participants who died or progressed. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. Data were analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before an event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.
| participants | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| Number of Participants Who Died or Progressed | 179 | 161 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chemoradiation: Topotecan Plus WBRT | — | 96/235 (40.9%) | 192/235 (81.7%) |
| Radiation: WBRT Alone | — | 43/233 (18.5%) | 139/233 (59.7%) |
| Event | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 22/235 | 2/233 |
| ThrombocytopeniaBlood and lymphatic system disorders | 22/235 | 1/233 |
| AnaemiaBlood and lymphatic system disorders | 16/235 | 1/233 |
| Febrile neutropeniaBlood and lymphatic system disorders | 13/235 | 0/233 |
| LeukopeniaBlood and lymphatic system disorders | 8/235 | 1/233 |
| PneumoniaInfections and infestations | 7/235 | 6/233 |
| DiarrhoeaGastrointestinal disorders | 6/235 | 0/233 |
| PancytopeniaBlood and lymphatic system disorders | 6/235 | 0/233 |
| DehydrationMetabolism and nutrition disorders | 5/235 | 3/233 |
| AstheniaGeneral disorders | 5/235 | 1/233 |
| Event | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone |
|---|---|---|
| NauseaGastrointestinal disorders | 64/235 | 30/233 |
| FatigueGeneral disorders | 39/235 | 37/233 |
| VomitingGastrointestinal disorders | 37/235 | 24/233 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 31/235 | 20/233 |
| AstheniaGeneral disorders | 29/235 | 19/233 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 29/235 | 22/233 |
| HeadacheNervous system disorders | 27/235 | 28/233 |
| Decreased appetiteMetabolism and nutrition disorders | 28/235 | 17/233 |
| DizzinessNervous system disorders | 27/235 | 19/233 |
| CoughRespiratory, thoracic and mediastinal disorders | 26/235 | 17/233 |
| Age, Continuous(Years) | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone | Total |
|---|---|---|---|
| Mean | 59.4 ± 8.56 | 57.8 ± 8.65 | 58.6 ± 8.63 |
| Sex: Female, Male(Participants) | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone | Total |
|---|---|---|---|
| Female | 84 | 78 | 162 |
| Male | 152 | 158 | 310 |
| Race/Ethnicity, Customized(participants) | Chemoradiation: Topotecan Plus WBRT | Radiation: WBRT Alone | Total |
|---|---|---|---|
| African American/African Heritage (Her.) | 3 | 1 | 4 |
| Central/South Asian Heritage | 1 | 0 | 1 |
| Japanese/East Asian Heritage/South East Asian Her. | 0 | 3 | 3 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| White | 230 | 232 | 462 |
| Asian & White | 1 | 0 | 1 |
The record gives a start of Dec 2006, a primary completion of Jul 2012 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Topotecan
Carcinoma, Non-Small-Cell Lung →